Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Inclusion Criteria: 1. Voluntary participation and signed informed consent form; 2. Age ≥18 years; 3. Eastern Cooperative Oncology Group performance status 0-1; 4. The International Federation of Gynecology and Obstetrics (FIGO 2023) stage III-IVb of endometrial cancer; 5. Has not received any systematic anti-tumor treatment for advanced diseases in the past; 6. Have measurable disease according to RECIST v1.1 criteria; 7. Patients must meet the following criteria for laboratory tests to ensure adequate organ function: * ANC ≥1,500/mm3, or ≥1.5×109/L * Platelet count≥75,000/mm3 or 75 x 109/L * Hemoglobin≥9 g/dL or ≥5.6 mmol/L * Glomerular filtration rate estimated（eGFR） according to the Chronic Kidney Disease Epidemiology Collaborative Group formula （CKD-EPI EQ6）was≥40 mL/ 1.73m2 * Serum total bilirubin ≤ 1.5x upper limit of normal range（ULN） * Both AST and ALT were ≤3 x ULN 8. The expected lifespan exceeds 3 months. Exclusion Criteria: 1. Received PD-1 target therapy other than tislelizumab or other antibody or drug therapy that specifically targets T-cell costimulation or checkpoint channels within 6 months before enrollment； 2. Has human immunodeficiency virus infection, active viral hepatitis, and active tuberculosis infection； 3. Active leptomeningeal disease or uncontrolled, untreated brain metastases resulting in elevated intracranial pressure; 4. Major surgical procedures had been performed within 4 weeks before consent was obtained； 5. Other conditions deemed by the investigator to be ineligible for enrollment.